Photo of Professor Michele Saunders

Professor Michele Saunders

Email:

Location:

  • University College Hospital

GMC/GDC number:

0271264

Professional background

Professor of oncology, University College London

Past Academic appointments

The director of the academic unit cancer centre Mount Vernon Hospital 1992-2009 

Director of the CRUK tumour biology and radiation therapy group 1992-2009

Reader in clinical oncology in the academic department of oncology, University College London 1992-1997

Professor in clinical oncology, academic department of oncology, University College London 1997-2002

Specialties

Research interests

  • Head & neck cancer
  • Radiobiology
  • Functional imaging and radiotherapy planning
  • Molecular genetics

Publications

Saunders MI, Dische S, Barrett A, Harvey A, Gibson D, Parmar M on behalf of the CHART Steering Committee (1997)  Continuous Hyperfractionated Accelerated Radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer : a randomised multicentre trial.  The Lancet, Vol.350, pp 161-165.

Dische S, Saunders MI, Barrett A, Harvey A, Gibson D, Parmar M on behalf of the CHART Steering Committee.   (1997)  A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer.   Radiotherapy and Oncology 44, 123-136.

Powell MEB, Hill SA, Saunders MI, Hoskin PJ and Chaplin DJ. (1997) Human tumour blood flow is enhanced by nicotinamide and carbogen breathing.  (1997)  Cancer Research 57, 5261-5264.

Saunders MI, Rojas A, Lyn BE, Pigott K, Powell MEB, Goodchild K, Hoskin PJ, Phillips H, Verma N.  Experience with dose escalation using CHARTWEL (Continuous Hyperfractionated Accelerated Radiotherapy Week-End Less) in non-small cell lung cancer. Br J Cancer 1998; 78:  1323-1328.

Powell MEB, Collingridge DR, Saunders MI, Hoskin PJ, Hill SA, Chaplin DJ.(1999)  Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations.  Radiother Oncol.  50, 167-171.

Saunders MI, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M, on behalf of the CHART Steering Committee. (1999) Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer:  Mature data from the Randomised Multicentre Trial.  Radiother. Oncol.  52, 137-148.

Hoskin PJ, SSaunders MI, Goodchild K, Powell MEB, Taylor NJ, Baddeley H. (1999)   Dynamic contrast-enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. British Journal of Radiology 72, 1093-1098.

Bentzen SM, Saunders MI, Dische S. (1999) Repair half-times estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer.  Radiotherapy and Oncology  53, 219-226.

Piggott KH, Dische S, Vojnovic B, Saunders MI  (2000)  Sweat gland function as a measure of radiation change. Radiotherapy and Oncology 54, 79-85.

Bentzen SM, Saunders MI, Dische S, Bond SJ.  Radiotherapy-related early morbidity in head and neck cancer: quantitative clinical radiobiology as deduced from the CHART trial.  Radiotherapy and Oncology  2001. 60: 123-135.

Taylor NJ, Baddeley H, Goodchild KA, Powell MEB, Thoumine M, Culver LA, Stirling JJ, Saunders MI,  Hoskin PJ et al. BOLD MRI of human tumour oxygenation during carbogen breathing.  J Mag Res Imaging 2001; 14: 156-163.

Bentzen SM, Saunders MI, Dische S.  From CHART to CHARTWEL in non-small cell lung cancer:  Clinical radiobiological modelling of the expected change in outcome.  Clinical Oncology 2002; 14: 372-381.
 
Sibtain A, Hill S, Goodchild K, Shah N, Saunders MI, Hoskin PJ.  The  modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen.  Radiotherapy Oncology 2002; 62: 69-76.

Harney J, Shah N, Short S, Saunders MI, Joiner M.  Low dose hyper-radiosensitivity – A clinical assessment.  Int J Radiation Biology Oncology Physics 2003; 55: 516-517.

Buffa FM, Bentzen SM, Daley FM, Dische S, Saunders MI, Richman PI and Wilson GD.  Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomised trial of continuous hyperfractionated accelerated radiotherapy.  Clin Cancer Res 2004; 10: 3745-3754.

Saunders MI, Rojas AM.  Management of cancer of the head and neck – a cocktail with your PORT?  N Eng J Med 2004  350: 1997-9.

Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis EA, Harris AL.  Endogenous markers of two separate hypoxia response pathways (HIF2 alpha and CA9) predict radiotherapy  failure in head and neck cancer patients recruited in the CHART randomized trial.  Journal of Clinical Oncology 2005.  24(5); 727-735.

Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ (2007) Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study Lancet Oncology 2007 8 (2):111-118.

Ng QS, Goh V, Milner J, Padhani AR, Saunders MI, Hoskin PJ. (2007) Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys. 67(2):417-24.

Wood K, WongWL, Saunders MI, [(64)Cu]diacetyl-bis(N(4)-methyl-thiosemicarbazone) a radiotracer for tumor hypoxia. Nucl Med Biol. 2008 May;35(4):393-400.